⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Efficacy of Eculizumab in Acute Refractory Pediatric Neuromyelitis Optica: A Case Report (P11-14.012)

Michael Enriquez Scott Rosenthal Ryan Kammeyer Amanda L. Piquet Jeffrey L. Bennett Loren A. McLedon

View Full Paper

Ask AI

Bookmark

Share

Abstract

To present the successful therapeutic use of intravenous (IV) eculizumab in a pediatric patient with acute aquaporin-4 (AQP4) IgG positive neuromyelitis optica spectrum disorder (NMOSD).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Enriquez et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db64358767746a https://doi.org/10.1212/wnl.0000000000205538

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Eculizumab in the treatment of neuromyelitis optica spectrum disorder2025
2Eculizumab for the acute attack of neuromyelitis optica spectrum disorder2025 · 7 citations
3Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trialRCT · 2020 · 41 citations
4Real-world Clinical Outcomes with Eculizumab and Ravulizumab in Anti-aquaporin-4 Antibody-positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD): Results from the Global NMO SPOTLIGHT Registry (S6.009)Original Research · 2026
5Eculizumab Efficacy and Safety in Patients with Neuromyelitis Optica Spectrum Disorder: A Systematic Review (P2-2.013)Human Clinical Trial · 2026